Cancer Therapy-Related Cardiac Dysfunction: Strategies for Enhancing Cardiac Recovery
References
- Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-1988. doi: 10.1161/CIRCULATIONAHA.114.013777
- Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [published correction appears in Eur Heart J. 2023 May 7;44(18):1621]. Eur Heart J. 2022;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244
- Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. Clin Med Insights Cardiol. 2019;13:1179546819866445. doi: 10.1177/1179546819866445
- Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820-7826. doi: 10.1200/JCO.2005.13.300
- Suntheralingam S, Fan CS, Calvillo-Argüelles O, Abdel-Qadir H, Amir E, Thavendiranathan P. Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer. J Clin Med. 2022;11(3):847. doi: 10.3390/jcm11030847
- Battisti NML, Andres MS, Lee KA, et al. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res Treat. 2021;188(1):149-163. doi: 10.1007/s10549-021-06192-w
- Xiao H, Wang X, Li S, Liu Y, Cui Y, Deng X. Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction. Front Cardiovasc Med. 2021;8:753313. doi: 10.3389/fcvm.2021.753313
- Cronin M, Seher M, Arsang-Jang S, et al. Multimodal Imaging of Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer-A State-of-the-Art Review. J Clin Med. 2023;12(19):6295. doi: 10.3390/jcm12196295
- Mir A, Badi Y, Bugazia S, et al. Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis. Cardiooncology. 2023;9(1):10. doi: 10.1186/s40959-023-00159-0
- Díaz-Balboa E, Peña-Gil C, Rodríguez-Romero B, et al. Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial. Prog Cardiovasc Dis. doi: 10.1016/j.pcad.2024.02.002
- Ibáñez B, Gomes-Silva M. Remote Ischemic Conditioning for Anthracycline Cardiotoxicity: The Need to Protect the Most Vulnerable. JACC CardioOncol. 2023;5(3):356-359. doi: 10.1016/j.jaccao.2023.05.002
- Salloum FN, Tocchetti CG, Ameri P, et al. Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2023;5(6):715-731. doi: 10.1016/j.jaccao.2023.08.003
DOI: https://doi.org/10.14797/mdcvj.1430 | Journal eISSN: 1947-6108
Language: English
Page range: 109 - 112
Submitted on: Jun 5, 2024
Accepted on: Jun 19, 2024
Published on: Aug 20, 2024
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
© 2024 Pavel Martinez-Dominguez, Maria Jose Santa Ana-Bayona, Enrique C. Guerra, Nilda Espinola-Zavaleta, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.